Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Schwartz

Interventional Cardiology Garden City, NY Doctor of Osteopathy

NPI 1083607311 CMS profile 140070

1401 Franklin Ave, Garden City, NY 11530

Open in the dashboard

General payments

$25,499

165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,038,735 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Richard Schwartz of Garden City, NY is reported in the CMS Open Payments database as having received $25,499 across 165 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,038,735 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,116 34
2024 General $1,216 17
2023 General $939 13
2022 General $7,803 33
2021 General $427 12
2020 General $519 13
2019 General $12,479 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Schwartz
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Richard Schwartz were reported at $2,116. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Richard Schwartz Interventional Cardiology median Middle half National median
2019 $12,479 $1,097 $329–$3,048 $163
2020 $519 $473 $161–$1,480 $114
2021 $427 $677 $233–$1,827 $132
2022 $7,803 $978 $333–$2,724 $149
2023 $939 $1,136 $382–$2,986 $160
2024 $1,216 $1,181 $395–$3,326 $164
2025 $2,116 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $9,368 61 payments
  2. Boston Scientific Corporation $9,364 7 payments
  3. Abbott Laboratories $3,738 40 payments
  4. Medtronic Vascular, Inc. $1,273 22 payments
  5. Edwards Lifesciences Corporation $1,259 21 payments
  6. W. L. Gore & Associates, Inc. $240 1 payment
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $154 7 payments
  8. Penumbra, Inc. $50 3 payments
  9. Pfizer Inc. $34 2 payments
  10. E.R. Squibb & Sons, L.L.C. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,166 2 payments
  2. Food and Beverage $7,202 139 payments
  3. Travel and Lodging $5,132 24 payments
Products named General payments · program years 2019–2025
  1. General Therapies $9,217 5 payments
  2. COREVALVE EVOLUT R $8,235 32 payments
  3. Mitra Clip system $1,874 15 payments
  4. TRICLIP $1,179 9 payments
  5. CoreValve Evolut $689 12 payments
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Transcatheter Heart Valves $363 6 payments
  7. SAPIEN 3 Ultra RESILIA $318 3 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Transcatheter Heart Valves $294 5 payments
  9. SYMPLICITY G3 $285 3 payments
  10. Resolute $244 5 payments
  11. Other $2,455 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,094

Median for Interventional Cardiology: 2,236

Drug cost

$224,005

Median for Interventional Cardiology: $380,412

Branded share of claims

23.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 83 $81,909
Repatha Sureclick Evolocumab Brand 37 $59,812
Xarelto Rivaroxaban Brand 14 $20,056
Praluent Pen Alirocumab Brand 17 $16,040
Nebivolol Hcl Generic 113 $8,132
Ranolazine Er Ranolazine Brand 47 $6,137
Vascepa Icosapent Ethyl Brand 11 $3,839
Metoprolol Succinate Generic 200 $3,577
Rosuvastatin Calcium Generic 259 $3,365
Colchicine Generic 14 $3,141

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$546,916

Medicare's payments for the services billed

Medicare patients

943

Average age 78

Services billed

3,751

417 women, 526 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 55%
Heart failure 54%
Diabetes 45%
Atrial fibrillation 40%
Chronic kidney disease 40%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record